Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer

Genomic alterations in metastatic prostate cancer remain incompletely characterized. Here we analyse 493 prostate cancer cases from the TCGA database and perform whole-genome plasma sequencing on 95 plasma samples derived from 43 patients with metastatic prostate cancer. From these samples, we identify established driver aberrations in a cancer-related gene in nearly all cases (97.7%), including driver gene fusions (TMPRSS2:ERG), driver focal deletions (PTEN, RYBP and SHQ1) and driver amplifications (AR and MYC). In serial plasma analyses, we observe changes in focal amplifications in 40% of cases. The mean time interval between new amplifications was 26.4 weeks (range: 5-52 weeks), suggesting that they represent rapid adaptations to selection pressure. An increase in neuron-specific enolase is accompanied by clonal pattern changes in the tumour genome, most consistent with subclonal diversification of the tumour. Our findings suggest a high plasticity of prostate cancer genomes with newly occurring focal amplifications as a driving force in progression.

Nature communications. 2016 Jun 22*** epublish ***

Peter Ulz, Jelena Belic, Ricarda Graf, Martina Auer, Ingrid Lafer, Katja Fischereder, Gerald Webersinke, Karl Pummer, Herbert Augustin, Martin Pichler, Gerald Hoefler, Thomas Bauernhofer, Jochen B Geigl, Ellen Heitzer, Michael R Speicher

Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria., Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria., Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria., Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria., Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria., Department of Urology, Medical University of Graz, A-8036 Graz, Austria., Department of Internal Medicine I, Hospital Barmherzige Schwestern Linz, A-4020 Linz, Austria., Department of Urology, Medical University of Graz, A-8036 Graz, Austria., Department of Urology, Medical University of Graz, A-8036 Graz, Austria., Department of Internal Medicine, Division of Oncology, Medical University of Graz, A-8036 Graz, Austria., Institute of Pathology, Medical University of Graz, A-8036 Graz, Austria., Department of Internal Medicine, Division of Oncology, Medical University of Graz, A-8036 Graz, Austria., Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria., Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria., Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe